|
Age, y (Mean SD)
|
67.09 ± 9.68
|
71.49 ± 10.27
| |
0.005
|
|
NIHSS score, median (IQR)
|
10(7–13)
|
18(14–20)
| |
<0.001
|
|
D-dimer, median (IQR)
|
1.80(1.10–2.70)
|
3.85(1.98–4.65)
| |
<0.001
|
|
INR, median (IQR)
|
1.35(1.09–1.93)
|
1.40(1.13–2.03)
| |
0.722
|
|
CHA2DS2-VASc, median (IQR)
|
4.00(4–5)
|
4.0(4–5)
| |
0.676
|
|
Infarct volume, ml, median (IQR)
|
61(34.5–102.5)
|
118(60.8–135.3)
| |
<0.001
|
|
CURB-65 score, median (IQR)
|
2(1–2)
|
3(2–3)
| |
<0.001
|
|
Females, n(%)
|
187(51.23)
|
24(48.00)
|
0.88 (0.49–1.59)
|
0.668
|
|
Male, n(%)
|
178(48.77)
|
26(52.00)
|
0.88 (0.49–1.59)
|
0.668
|
|
BMI ≥ 24 kg/m, n(%)
|
110(30.14)
|
13(26.00)
|
0.81(0.42–1.59)
|
0.548
|
|
Hypertension, n(%)
|
233(63.84)
|
32(64.00)
|
1.01(0.54–1.86)
|
0.982
|
|
Current Smoking, n(%)
|
106(29.04)
|
20(40.00)
|
1.63(0.89–3.00)
|
0.114
|
|
Current alcohol drinking, n(%)
|
124 (33.97)
|
23(46.00)
|
1.66(0.91–3.01)
|
0.095
|
|
Diabetes, n(%)
|
112(30.68)
|
11(22.00)
|
0.64(0.32–1.29)
|
0.207
|
|
Hyperlipidemia, n(%)
|
147(40.27)
|
31(62.00)
|
0.78(0.42–1.44)
|
0.424
|
|
Family history of stroke, n(%)
|
86(23.56)
|
8(16.00)
|
0.62(0.28–1.37)
|
0.231
|
|
Thrombolytic therapy, n(%)
|
43(11.78)
|
816.00)
|
1.43(0.63–3.24)
|
0.394
|
|
Thrombectomy, n(%)
|
18(4.93)
|
5(10.00)
|
2.14(0.76–6.05)
|
0.142
|
|
Thrombolytic therapy+ Thrombectomy, n(%)
|
7(1.92)
|
1(2.00)
|
1.04(0.13–8.67)
|
0.968
|
|
Medications use
|
|
Antiplatelets, n(%)
|
96(26.30)
|
13(26.00)
|
0.99(0.50–1.93)
|
0.964
|
|
Lipid-lowering medications, n(%)
|
213(58.36)
|
28(56.00)
|
0.91(0.50–1.65)
|
0.752
|
